Leap Therapeutics has announced it will lay off 75% of its workforce in two phases:
one on or about June 30, 2025 and the other on or about July 31, 20251234.
The company is winding down its research and development activities, including terminating its only remaining clinical trial—a Phase II study of the DKK1 antibody sirexatamab in advanced colorectal cancer12.
Once layoffs are complete, Leap will have fewer than 10 employees remaining, a significant reduction from its 52 full-time staff at the end of 2024123.
Two C-suite executives, COO Augustine Lawlor and CMO Cyndi Sirard, will depart as part of this restructuring13.
The layoffs and R&D wind-down come as Leap seeks to reduce spending, preserve capital, and explore strategic alternatives, which include a potential sale or partnership for both its lead asset sirexatamab and preclinical candidate FL-50112.
The company reported positive trends in its clinical trial, but cited market conditions as the reason for discontinuing the study12.
Sources:
1. https://www.biospace.com/job-trends/leap-slashes-75-of-workforce-explores-strategic-options
2. https://www.fiercebiotech.com/biotech/leap-expands-layoffs-cover-75-staff-scraps-only-clinical-trial
3. https://www.biospace.com/biospace-layoff-tracker
4. https://www.bizjournals.com/boston/news/2025/06/23/leap-therapeutics-strategic-alt.html